Received Sep 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 324BY | — |
Twinrix administration under the 18 years of age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 18-month-old male patient who received HAB (Twinrix) (batch number 324BY, expiry date 28-SEP-2026) for prophylaxis. On 05-SEP-2025, the patient received Twinrix. On 05-SEP-2025, an unknown time after receiving Twinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Twinrix administration under the 18 years of age). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-SEP-2025 A health care provider wanted to get safety information on the administration of Twinrix in five patients below 18 years of age. The vaccine administration facility was the same as primary reporter. This was 1 of 5 linked cases, reported by the same reporter.; Sender's Comments: US-GSK-US2025116673:same reporter US-GSK-US2025116669:same reporter US-GSK-US2025116668:same reporter US-GSK-US2025116676:same reporter